AAP
RCKT icon

Arax Advisory Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Arax Advisory Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
52,755
+51,446
+3,930% +$171K ﹤0.01% 2321
2026
Q1 		$4.69K Buy
1,309
+1,274
+3,640% +$5.06K ﹤0.01% 2813
2025
Q4 		$123 Sell
35
-35,820
-100% -$123K ﹤0.01% 3797
2025
Q3 		$117K Buy
+35,855
New +$113K ﹤0.01% 1483
2025
Q1 		– Sell
-120
Closed -$1.51K – 2973
2024
Q4 		$1.51K Buy
+120
New +$1.81K ﹤0.01% 2076

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Arax Advisory Partners's RCKT Position: Q2 2026 in Review

Arax Advisory Partners increased its Rocket Pharmaceuticals (RCKT) stake by 3,930% in Q2 2026, buying an estimated $171K and bringing the position to 52,755 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #2321.

Arax Advisory Partners first reported a position in RCKT in Q4 2024 and has held it in 5 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Arax Advisory Partners held 52,755 shares of Rocket Pharmaceuticals worth $180K as of Q2 2026.
  • Arax Advisory Partners bought 51,446 Rocket Pharmaceuticals shares in Q2 2026, an estimated $171K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2321 holding.
  • Arax Advisory Partners first reported a position in Rocket Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.